You are here: Industry Insights > M&A

News List

Pharmaceutical News of the Week (June. 29th-July. 3rd) | PharmaSources.com - Updates on M&A, IPO and Others PharmaSources/Caicai
July 08, 2020
Let’s review the hot events of the pharmaceutical industry this week. The news involved 5 sections: approval, R&D, policies, transactions and listing that happened during June 29-July 3, including 29 pieces.
What’s been happening in pharma? - Updates on M&A, Regulatory approvals and collaborations Sarah Harding
June 29, 2020
Key updates in June are summarized here, along with some of the latest industry announcements on new partnerships, M&As and regulatory approvals.
Bora Pharmaceuticals collaborates with Taishin Holdings to launch CDMO investment and M&A plan prnasia
December 09, 2021
Bobby Sheng, chairman of Bora Pharmaceuticals (6472.TWO), today announced a partnership with Taishin Healthcare Limited Partnership at the 2021 Biotech Investor Forum...
Madison Street Capital Awarded "Distressed M&A Deal Of The Year" By The M&A Advisor's 15th Annual Turnaround Awards prnewswire
September 13, 2021
AUSTIN, Texas, Sept. 7, 2021 /PRNewswire/ -- The M&A Advisor announced the recipients of its 15th Annual Turnaround Awards, recognizing those that reached the pinnacle of the distressed investing, bankruptcy, and restructuring industry over the past year.
CPhI Webinar: How is M&A Shifting the Pharma Manufacturing Landscape? cphi-online
July 07, 2021
The broad scope of the pharmaceutical manufacturing landscape is making merger and acquisition activity in the sector ever more complex with several varying factors driving decisions, according to a recent CPhI Webinar sponsored by PharmaVentures.
CPhI Monthly Podcast: M&A strategies in the CDMO sector cphi-online
June 28, 2021
This month we discuss what is driving M&A strategies in the pharma space, paying particular attention to how investors regard the potential for the growing but fragmented CDMO sector
Pandemic inevitably slows pharma M&A activity but appetite for deals remains cphi-online
June 07, 2021
The initial outbreak of the COVID-19 pandemic delayed merger and acquisitions in the pharma sector, but evidence points to an uptick in activity because the rationale for sealing deals hasn’t changed
Agilent continues to focus on strategic M&A, R&D investment to expand product portfolio expresspharma
March 15, 2021
Samir Vyas, Country Manager, Agilent India says India companies are now moving into the global biopharma market and gives his views on the role of policies like Make in India/Atmanirbhar Bharat, a more vigilant US FDA after the sartan episode and ...
Value of pharma’s M&A deals remain high, despite COVID-19 europeanpharmaceuticalreview
January 11, 2021
Analysts say M&A deals continue to be a core driver of pharma/biopharma industry growth and that 2021 will likely be another year of high deal value.
M&As in bio/pharma industry high despite COVID-19: GlobalData expresspharma
December 28, 2020
Down only 13 per cent compared with last year, with a total deal value of $228 billion compared with $262 billion in 2020, and almost twice the 2017 total deal value of $126 billion.